Eikon Therapeutics, Inc. (EIKN)
NASDAQ: EIKN · Real-Time Price · USD
11.38
+0.50 (4.60%)
Sep 2, 2026, 4:00 PM EDT - Market closed

Eikon Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023
Period EndingJun '26 Dec '25 Dec '24 Dec '23
Operating Income
-338.45-314.43-260.34-265.74
Net Income
-322.16-333.64-243.81-242
Earnings Per Share
-13.72-115.29-96.76-119.43
EPS Growth
----

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023
Period EndingJun '26 Dec '25 Dec '24 Dec '23
Cash & Investments
531.18335.98220.11430.41
Total Debt
252.22257.32202.4631.74
Net Cash (Debt)
278.9678.6617.65398.68
Net Cash Growth
1480.33%345.59%-95.57%-
Net Cash Per Share
11.8827.187.01196.75

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023
Period EndingJun '26 Dec '25 Dec '24 Dec '23
Operating Cash Flow
-256.02-188.52-134.8-190.85
Capital Expenditures
-3.18-46.74-84.8-28.51
Free Cash Flow
-259.2-235.26-219.6-219.36
Free Cash Flow Growth
----